226 related articles for article (PubMed ID: 32397531)
1. Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers.
Matuszczak M; Salagierski M
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397531
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy.
Liu A; Xue Y; Liu F; Tan H; Xiong Q; Zeng S; Zhang Z; Gao X; Sun Y; Xu C
Cancer Biomark; 2019; 26(3):281-289. PubMed ID: 31594208
[TBL] [Abstract][Full Text] [Related]
4. FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer.
Mhawech-Fauceglia P; Cheney RT; Fischer G; Beck A; Herrmann FR
Eur J Surg Oncol; 2006 Mar; 32(2):231-7. PubMed ID: 16412606
[TBL] [Abstract][Full Text] [Related]
5. Tumor-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer.
Kelloniemi E; Rintala E; Finne P; Stenman UH;
Urology; 2003 Aug; 62(2):249-53. PubMed ID: 12893328
[TBL] [Abstract][Full Text] [Related]
6. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
[TBL] [Abstract][Full Text] [Related]
7. Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumour progression.
Gardiner RA; Walsh MD; Allen V; Rahman S; Samaratunga ML; Seymour GJ; Lavin MF
Br J Urol; 1994 May; 73(5):526-32. PubMed ID: 8012775
[TBL] [Abstract][Full Text] [Related]
8. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
[TBL] [Abstract][Full Text] [Related]
9. P53 expression, ploidy and progression in pT1 transitional cell carcinoma of the bladder.
Thomas DJ; Robinson MC; Charlton R; Wilkinson S; Shenton BK; Neal DE
Br J Urol; 1994 May; 73(5):533-7. PubMed ID: 8012776
[TBL] [Abstract][Full Text] [Related]
10. [Bladder tumor histo-seminar - case 6: Invasive urothelial carcinoma, with inverted growth (UroA/FGFR3 molecular type)].
Allory Y
Ann Pathol; 2016 Dec; 36(6):394-397. PubMed ID: 27838079
[No Abstract] [Full Text] [Related]
11. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
12. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
Sarkis AS; Dalbagni G; Cordon-Cardo C; Zhang ZF; Sheinfeld J; Fair WR; Herr HW; Reuter VE
J Natl Cancer Inst; 1993 Jan; 85(1):53-9. PubMed ID: 7677935
[TBL] [Abstract][Full Text] [Related]
13. Bivariate analysis DNA/cytokeratin 7 and flow cytometric measurement of MIB-1 in superficial transitional carcinoma of the bladder (TCC). Methodological aspects and prognostic implications.
Leonardi E; Cristofori A; Reich A; Dalla Palma P
Eur J Histochem; 1997; 41 Suppl 2():133-4. PubMed ID: 9859817
[No Abstract] [Full Text] [Related]
14. p53 overexpression as a prognostic factor for advanced stage bladder cancer.
Kuczyk MA; Bokemeyer C; Serth J; Hervatin C; Oelke M; Höfner K; Tan HK; Jonas U
Eur J Cancer; 1995 Dec; 31A(13-14):2243-7. PubMed ID: 8652250
[TBL] [Abstract][Full Text] [Related]
15. [Clinical applications of molecular biomarkers in urothelial carcinoma of bladder].
Cheng L; Xu JW; He JJ; Zhao J; Teng XD
Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):714-7. PubMed ID: 22321559
[No Abstract] [Full Text] [Related]
16. Biological characterisation of superficial bladder cancer by bivariate cytokeratin 7/DNA analysis, flow cytometric assessment of MIB- 1, and an immunohistochemical study.
Leonardi E; Dalla Palma P; Reich A; Caffo O; Luciani L
Anal Cell Pathol; 2000; 21(1):21-33. PubMed ID: 11254222
[TBL] [Abstract][Full Text] [Related]
17. Urine cytology. It is still the gold standard for screening?
Brown FM
Urol Clin North Am; 2000 Feb; 27(1):25-37. PubMed ID: 10696242
[TBL] [Abstract][Full Text] [Related]
18. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
[TBL] [Abstract][Full Text] [Related]
19. [Multivariate analysis of recurrence and progression in stage T1 transitional-cell carcinoma of the bladder. Prognostic value of p53 and Ki67].
Rodríguez Alonso A; Pita Fernández S; González-Carreró J; Nogueira March JL
Actas Urol Esp; 2003 Feb; 27(2):132-41. PubMed ID: 12731328
[TBL] [Abstract][Full Text] [Related]
20. Molecular prognostic factors in bladder cancer.
Schalken JA
Eur Urol; 1998; 33 Suppl 4():13-4. PubMed ID: 9615200
[No Abstract] [Full Text] [Related]
[Next] [New Search]